obesitymedicine #medicalnews #clinicaltrials #cagrisema #zepbound # tirzepatide #semaglutide #weightloss #healthcare Joseph Zucchi, PA C, MPAS 10 comments Three new #obesity drugshigh dose semaglutide, semaglutide plus cagrilintide, and oral orforglipronmay soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how CagriSema vs Tirzepatide: 23% Weight Loss in Phase 3 Trial Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Unlocking the Power of Cagrilintide: A Deep Dive Into Dosage Schedules and What to Expect Feast